Primary sclerosing cholangitis

Disease ID:784
Name:Primary sclerosing cholangitis
Associated with:1 target
1 immuno-relevant ligand
Database Links
Orphanet: ORPHA171

Targets

GPR35
References:  1

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
timolumab
Immuno Disease Comments: Phase 2 clinical candidate for PSC.
Clinical Use: Timolumab (with research code BTT1023) is being evaluated in Phase II clinical trial NCT02239211, for its potential to treat patients with primary sclerosing cholangitis, an uncommon and progressive disease of the bile ducts characterised by inflammation and obliterative fibrosis. Phase I studies for RA and psoriasis have been completed (2010/11). | View clinical data

References

Show »

1. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, Weismüller TJ et al.. (2013) Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology, 58 (3): 1074-83. [PMID:22821403]